STAT+: AI biotech Insitro’s Daphne Koller on how to speed up clinical trials

Daphne Koller, founder and CEO of AI biotech Insitro, discussed strategies to accelerate clinical trials in an interview with STAT, emphasizing the role of artificial intelligence in improving trial design and patient selection. Koller highlighted that AI can reduce the time and cost of drug development by identifying better biomarkers and optimizing patient recruitment, which is critical for bringing therapies to market faster.

Y ou’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. I really miss the Vox Earworm videos that explained the science and history of pop music, like “ The sound that connects Stravinsky to Bruno Mars https://www.youtube.com/watch?v=8A1Aj1 EF9Y ” or “ How a recording-studio mishap shaped ’80s music https://www.youtube.com/watch?v=Bxz6jShW-3E .” A spiritual successor? This video exploring the origin of the somehow-ubiquitous “Gen Alpha Melody” https://www.youtube.com/watch?v=DW0XUsyBBuY from Carl E. Martin, at the time a musicology grad student. Be sure to watch all the way until the last second. This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in /login/ View All Plans https://www.statnews.com/stat-plus/